PanGen Biotech Inc. (KOSDAQ: 222110)
South Korea
· Delayed Price · Currency is KRW 5,640.00
+40.00 (0.71%)
Dec 19, 2024, 1:50 PM KST
PanGen Biotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 13,724 | 7,315 | 6,501 | 7,936 | 6,191 | 2,881 | Upgrade
|
| Other Revenue | -0 | -0 | - | - | - | - | Upgrade
|
| Revenue | 13,724 | 7,315 | 6,501 | 7,936 | 6,191 | 2,881 | Upgrade
|
| Revenue Growth (YoY) | 179.56% | 12.53% | -18.08% | 28.18% | 114.87% | -49.27% | Upgrade
|
| Cost of Revenue | 8,434 | 6,343 | 5,858 | 7,420 | 4,838 | 4,996 | Upgrade
|
| Gross Profit | 5,290 | 971.8 | 642.47 | 515.69 | 1,353 | -2,114 | Upgrade
|
| Selling, General & Admin | 1,722 | 1,536 | 1,272 | 969.85 | 1,108 | 1,043 | Upgrade
|
| Research & Development | 3,296 | 3,332 | 3,850 | 2,734 | 3,676 | 4,523 | Upgrade
|
| Other Operating Expenses | 27.49 | 26.64 | 25.92 | 28 | 34.25 | 34.78 | Upgrade
|
| Operating Expenses | 5,358 | 5,197 | 5,233 | 3,804 | 5,053 | 5,864 | Upgrade
|
| Operating Income | -68.12 | -4,225 | -4,591 | -3,288 | -3,700 | -7,978 | Upgrade
|
| Interest Expense | -339.62 | -220.68 | -128.77 | -293.25 | -1,013 | -1,214 | Upgrade
|
| Interest & Investment Income | 113.63 | 41.75 | 246.57 | 179.7 | 255.54 | 519.97 | Upgrade
|
| Currency Exchange Gain (Loss) | -39.27 | 12.47 | 7.34 | 92.88 | -83.99 | 19.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -231.86 | -64.6 | 37.97 | 59.88 | 185.79 | 309.23 | Upgrade
|
| EBT Excluding Unusual Items | -565.24 | -4,457 | -4,428 | -3,249 | -4,356 | -8,344 | Upgrade
|
| Gain (Loss) on Sale of Assets | 13.77 | 15.15 | -0.24 | -0.67 | -0.03 | -0.25 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -589.96 | Upgrade
|
| Other Unusual Items | - | - | -7.39 | - | - | - | Upgrade
|
| Pretax Income | -551.47 | -4,441 | -4,435 | -3,250 | -4,356 | -8,934 | Upgrade
|
| Income Tax Expense | 47.43 | 47.43 | 58.69 | 60.5 | - | 3.22 | Upgrade
|
| Net Income | -598.9 | -4,489 | -4,494 | -3,310 | -4,356 | -8,938 | Upgrade
|
| Net Income to Common | -598.9 | -4,489 | -4,494 | -3,310 | -4,356 | -8,938 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 11 | 10 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | 3.61% | 0.03% | 4.47% | 6.02% | -0.04% | 0.16% | Upgrade
|
| EPS (Basic) | -54.17 | -420.40 | -421.00 | -324.00 | -452.00 | -927.00 | Upgrade
|
| EPS (Diluted) | -57.42 | -420.40 | -421.00 | -324.00 | -452.00 | -927.00 | Upgrade
|
| Free Cash Flow | 423.21 | -3,873 | -4,231 | -4,749 | -5,437 | -4,481 | Upgrade
|
| Free Cash Flow Per Share | 38.28 | -362.70 | -396.34 | -464.83 | -564.12 | -464.80 | Upgrade
|
| Gross Margin | 38.54% | 13.28% | 9.88% | 6.50% | 21.86% | -73.39% | Upgrade
|
| Operating Margin | -0.50% | -57.76% | -70.62% | -41.44% | -59.77% | -276.89% | Upgrade
|
| Profit Margin | -4.36% | -61.36% | -69.13% | -41.71% | -70.36% | -310.19% | Upgrade
|
| Free Cash Flow Margin | 3.08% | -52.94% | -65.08% | -59.85% | -87.81% | -155.53% | Upgrade
|
| EBITDA | 1,428 | -2,629 | -2,987 | -1,756 | -2,132 | -6,324 | Upgrade
|
| EBITDA Margin | 10.41% | -35.94% | -45.96% | -22.13% | -34.44% | -219.50% | Upgrade
|
| D&A For EBITDA | 1,496 | 1,597 | 1,603 | 1,532 | 1,568 | 1,654 | Upgrade
|
| EBIT | -68.12 | -4,225 | -4,591 | -3,288 | -3,700 | -7,978 | Upgrade
|
| EBIT Margin | -0.50% | -57.76% | -70.62% | -41.44% | -59.77% | -276.89% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.